EUVIMEDEUVIMED entdecken
Open Access

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

Anne-Marie Rick, Jennifer Deese, Jessica E Kerr, Jonathan Hui, Hui Liu, Guan Yu, Chung-Chou H Chang, Nicole Fazio, Muhammad H Tahir, Rachael Bieltz, Anjani Ravindra, Christina Megli und 7 weitere

JAMA Network Open · 05.06.2026 · 9 (6) · e2616773

DOI: 10.1001/jamanetworkopen.2026.16773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.06.2026. Verfasst von Anne-Marie Rick und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of General Academic Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Tract Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine was licensed in the US in September 2023 to prevent RSV-associated lower respiratory tract disease (LRTD) in infants via maternal immunization. Clinical data on vaccine effectiveness are limited.

Objective

To estimate the effectiveness of maternal RSVpreF vaccination against hospitalization for RSV-associated acute respiratory illness (ARI) and LRTD among infants 90 days or younger during the first 2 postlicensure RSV seasons. Design, Setting, and Participants This retrospective case-control study (Effectiveness of ABRYSVO Maternal Respiratory Syncytial Virus Vaccine Against RSV in Infants in Western Pennsylvania study) using a test-negative design was conducted within a single health system in western Pennsylvania during the 2023-2024 and 2024-2025 RSV seasons. The analysis included infants 90 days or younger born between October 1, 2023, and April 15, 2024, or between September 1, 2024, and April 30, 2025, who were hospitalized with ARI and tested for RSV using nucleic acid amplification or rapid antigen testing. Exposure Maternal RSVpreF vaccination administered at gestational age between 32 weeks 0 to 7 days and 36 weeks 6 to 7 days and at least 14 days before delivery. Main Outcomes and Measures The primary outcome was RSV-associated ARI requiring hospitalization. The secondary outcome was RSV-associated LRTD requiring hospitalization. Vaccine effectiveness was estimated as (1 − Adjusted Odds Ratio) × 100% comparing the odds of maternal RSVpreF vaccination among RSV-positive infants (cases) vs RSV-negative infants (controls) using multivariable logistic regression.

Results

Among 274 included infants (83 with RSV and 191 controls), the mean (SD) age at admission was 29.5 (21.1) days; 143 infants (52.2%) were male. Among these, 11 of 83 infants with RSV (13.3%) and 71 of 191 controls (37.2%) were born to RSVpreF-vaccinated individuals. Vaccine effectiveness was estimated to be 67.6% (95% CI, 33.2%-85.4%) against RSV-associated ARI hospitalization and 69.0% (95% CI, 25.5%-88.0%) against RSV-associated LRTD hospitalization from 0 through 90 days of age. Among infants aged 0 to 30 days, vaccine effectiveness against RSV-associated ARI hospitalization was estimated to be 74.2% (95% CI, 25.4%-93.0%). Conclusions and Relevance Maternal RSVpreF vaccination was associated with protection against RSV-associated ARI and LRTD hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsVaccinationHumansFemaleRetrospective StudiesCase-Control StudiesInfantMalePennsylvaniaPregnancyInfant, NewbornHospitalizationAdultAcute Disease

Substanzen

Respiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Department of Pediatrics, Division of General Academic Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Pfizer Inc, Collegeville, Pennsylvania.
  • Department of Biostatistics and Health Data Science, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
  • Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Department of Family Medicine, Mercy Catholic Medical Center, Conshohocken, Pennsylvania.
  • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Zitieren

APA

Rick, A. M., Deese, J., Kerr, J. E., Hui, J., Liu, H., Yu, G., Chang, C. H., Fazio, N., Tahir, M. H., Bieltz, R., Ravindra, A., Megli, C., Jeyabalan, A., Pugh, S. J., Patel, D., Fan, R., Atwell, J. E., Cané, A., & Martin, J. M. (2026). Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants. JAMA Network Open, 9(6), e2616773. https://doi.org/10.1001/jamanetworkopen.2026.16773

Vancouver

Rick AM, Deese J, Kerr JE, Hui J, Liu H, Yu G, et al. Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants. JAMA Network Open. 2026;9(6):e2616773. doi:10.1001/jamanetworkopen.2026.16773

BibTeX
@article{Rick2026,
  author = {Rick, Anne-Marie and Deese, Jennifer and Kerr, Jessica E and Hui, Jonathan and Liu, Hui and Yu, Guan and Chang, Chung-Chou H and Fazio, Nicole and Tahir, Muhammad H and Bieltz, Rachael and Ravindra, Anjani and Megli, Christina and Jeyabalan, Arun and Pugh, Sarah J and Patel, Divya and Fan, Rong and Atwell, Jessica E and Cané, Alejandro and Martin, Judith M},
  title = {Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {6},
  pages = {e2616773},
  doi = {10.1001/jamanetworkopen.2026.16773}
}
Kostenlos starten →